Pureに変更を加えた場合、すぐここに表示されます。

Fingerprint Yasuo Hamamotoが取り組む研究トピックをご確認ください。これらのトピックラベルは、この人物の研究に基づいています。これらを共に使用することで、固有の認識が可能になります。

  • 47 同様のプロファイル
irinotecan Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
Esophageal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences

ネットワーク 最近の共同研究。丸をクリックして詳細を確認しましょう。

研究成果 1998 2019

  • 3642 引用
  • 25 h指数
  • 85 Article
  • 5 Review article
  • 3 Letter
  • 2 Comment/debate
1 引用 (Scopus)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

Kato, K., Satoh, T., Muro, K., Yoshikawa, T., Tamura, T., Hamamoto, Y., Chin, K., Minashi, K., Tsuda, M., Yamaguchi, K., Machida, N., Esaki, T., Goto, M., Komatsu, Y., Nakajima, T. E., Sugimoto, N., Yoshida, K., Oki, E., Nishina, T., Tsuji, A. および11人, Fujii, H., Kunieda, K., Saitoh, S., Omuro, Y., Azuma, M., Iwamoto, Y., Taku, K., Fushida, S., Chen, L. T., Kang, Y. K. & Boku, N., 2019 3 15, : : Gastric Cancer. 22, 2, p. 344-354 11 p.

研究成果: Article

公開
Esophageal Neoplasms
Stomach
Placebos
Drug Therapy
Survival

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial

Yoshikawa, T., Muro, K., Shitara, K., Oh, D. Y., Kang, Y. K., Chung, H. C., Kudo, T., Chin, K., Kadowaki, S., Hamamoto, Y., Hironaka, S., Yoshida, K., Yen, C. J., Omuro, Y., Bai, L. Y., Maeda, K., Ozeki, A., Yoshikawa, R. & Kitagawa, Y., 2019 8 2, : : JAMA network open. 2, 8, p. e198243

研究成果: Article

公開
oxaliplatin
Far East
Paclitaxel
Stomach Neoplasms
Randomized Controlled Trials

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

Satoh, T., Kang, Y. K., Chao, Y., Ryu, M. H., Kato, K., Cheol Chung, H., Chen, J. S., Muro, K., Ki Kang, W., Yeh, K. H., Yoshikawa, T., Oh, S. C., Bai, L. Y., Tamura, T., Lee, K. W., Hamamoto, Y., Kim, J. G., Chin, K., Oh, D. Y., Minashi, K. および5人, Cho, J. Y., Tsuda, M., Tanimoto, M., Chen, L. T. & Boku, N., 2019 1 1, : : Gastric Cancer.

研究成果: Article

公開
Esophagogastric Junction
Phase III Clinical Trials
Stomach
Randomized Controlled Trials
Safety
4 引用 (Scopus)

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., Kadowaki, S., Ahn, M. J., Hamamoto, Y., Doki, Y., Yen, C. C., Kubota, Y., Kim, S. B., Hsu, C. H., Holtved, E., Xynos, I., Kodani, M. & Kitagawa, Y., 2019 11, : : The Lancet Oncology. 20, 11, p. 1506-1517 12 p.

研究成果: Article

Drug Therapy
Survival
Interstitial Lung Diseases
Research Personnel
docetaxel
公開
Intestinal Perforation
Gastrointestinal Stromal Tumors
Kidney
Cyclosporine
Small Intestine